Cargando…
Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience
SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486951/ https://www.ncbi.nlm.nih.gov/pubmed/37686593 http://dx.doi.org/10.3390/cancers15174316 |
_version_ | 1785103119023079424 |
---|---|
author | Schmidt, Moritz Hinterleitner, Clemens Singer, Stephan Lauer, Ulrich M. Zender, Lars Hinterleitner, Martina |
author_facet | Schmidt, Moritz Hinterleitner, Clemens Singer, Stephan Lauer, Ulrich M. Zender, Lars Hinterleitner, Martina |
author_sort | Schmidt, Moritz |
collection | PubMed |
description | SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN-UPs. After extensive diagnostic work-up, in 11.5% (13 patients) a primary tumor site could be identified. Our study revealed that an extensive diagnostic work-up, in particular somatostatin receptor (SSTR)-PET, is associated with a better clinical outcome. Our study proposes that a detailed diagnostic investigation and the identification of a primary tumor site can provide the rationale for a tumor-specific therapy, contributing to a prolonged survival in NEN-UPs. ABSTRACT: Neuroendocrine neoplasms (NENs) represent a rare and heterogenous group of tumors with predominantly gastroenteropancreatic or pulmonary origin. Despite numerous diagnostic efforts, the primary tumor site remains unknown in up to 20% of the patients diagnosed with NEN. In this subgroup of NEN patients, a standard diagnostic algorithm has not yet been integrated into clinical routine. Of note, an undetermined primary tumor site in NENs is associated with an impaired clinical outcome by at least “formally” limiting treatment options exclusively approved for NENs of a certain histological origin. In this retrospective study, a patient cohort of 113 patients initially diagnosed with NEN of unknown primary (NEN-UP) was analyzed. In 13 patients (11.5%) a primary tumor site could be identified subsequently, amongst others, by performing somatostatin receptor (SSTR)-PET-based imaging, which was irrespective of the initial clinical or demographic features. Diagnostic work-up and therapeutic regimens did not differ significantly between patients with an identified or unidentified primary tumor site; only a detailed immunohistochemical assessment providing additional information on the tumor origin proved to be significantly associated with the detection of a primary tumor site. Our study revealed that a profound diagnostic work-up, particularly including SSTR-PET-based imaging, leads to additional treatment options, finally resulting in significantly improved clinical outcomes for patients with NEN-UPs. |
format | Online Article Text |
id | pubmed-10486951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-104869512023-09-09 Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience Schmidt, Moritz Hinterleitner, Clemens Singer, Stephan Lauer, Ulrich M. Zender, Lars Hinterleitner, Martina Cancers (Basel) Article SIMPLE SUMMARY: Neuroendocrine neoplasms (NENs) of unknown primary (NEN-UPs) encompass a small group within all diagnosed NENs. As a result, diagnostic work-up and the therapy algorithm are not standardized. In this study we consecutively analyzed a cohort of 113 patients, initially diagnosed as NEN-UPs. After extensive diagnostic work-up, in 11.5% (13 patients) a primary tumor site could be identified. Our study revealed that an extensive diagnostic work-up, in particular somatostatin receptor (SSTR)-PET, is associated with a better clinical outcome. Our study proposes that a detailed diagnostic investigation and the identification of a primary tumor site can provide the rationale for a tumor-specific therapy, contributing to a prolonged survival in NEN-UPs. ABSTRACT: Neuroendocrine neoplasms (NENs) represent a rare and heterogenous group of tumors with predominantly gastroenteropancreatic or pulmonary origin. Despite numerous diagnostic efforts, the primary tumor site remains unknown in up to 20% of the patients diagnosed with NEN. In this subgroup of NEN patients, a standard diagnostic algorithm has not yet been integrated into clinical routine. Of note, an undetermined primary tumor site in NENs is associated with an impaired clinical outcome by at least “formally” limiting treatment options exclusively approved for NENs of a certain histological origin. In this retrospective study, a patient cohort of 113 patients initially diagnosed with NEN of unknown primary (NEN-UP) was analyzed. In 13 patients (11.5%) a primary tumor site could be identified subsequently, amongst others, by performing somatostatin receptor (SSTR)-PET-based imaging, which was irrespective of the initial clinical or demographic features. Diagnostic work-up and therapeutic regimens did not differ significantly between patients with an identified or unidentified primary tumor site; only a detailed immunohistochemical assessment providing additional information on the tumor origin proved to be significantly associated with the detection of a primary tumor site. Our study revealed that a profound diagnostic work-up, particularly including SSTR-PET-based imaging, leads to additional treatment options, finally resulting in significantly improved clinical outcomes for patients with NEN-UPs. MDPI 2023-08-29 /pmc/articles/PMC10486951/ /pubmed/37686593 http://dx.doi.org/10.3390/cancers15174316 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Schmidt, Moritz Hinterleitner, Clemens Singer, Stephan Lauer, Ulrich M. Zender, Lars Hinterleitner, Martina Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title | Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title_full | Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title_fullStr | Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title_full_unstemmed | Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title_short | Diagnostic Approaches for Neuroendocrine Neoplasms of Unknown Primary (NEN-UPs) and Their Prognostic Relevance—A Retrospective, Long-Term Single-Center Experience |
title_sort | diagnostic approaches for neuroendocrine neoplasms of unknown primary (nen-ups) and their prognostic relevance—a retrospective, long-term single-center experience |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10486951/ https://www.ncbi.nlm.nih.gov/pubmed/37686593 http://dx.doi.org/10.3390/cancers15174316 |
work_keys_str_mv | AT schmidtmoritz diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience AT hinterleitnerclemens diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience AT singerstephan diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience AT lauerulrichm diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience AT zenderlars diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience AT hinterleitnermartina diagnosticapproachesforneuroendocrineneoplasmsofunknownprimarynenupsandtheirprognosticrelevancearetrospectivelongtermsinglecenterexperience |